Deanna Wallace
Medical · Sugar Land, TXNPI 1861631004
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 844 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 844 payments — averaging $19.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
- AbbVie$2K
- UCB, Inc.$2K
- AstraZeneca$2K
- Pfizer$1K
- Johnson & Johnson$1K
- plus $4K from 29 others
What the payments were for
- Food & beverage$16,573100%
- Education$780%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 194 | $3,976 |
| AbbVie | 125 | $2,232 |
| UCB, Inc. | 79 | $1,878 |
| AstraZeneca(2 entities) | 80 | $1,682 |
| Pfizer | 95 | $1,456 |
| Johnson & Johnson(2 entities) | 60 | $1,388 |
| Lilly USA, LLC | 49 | $806 |
| Sanofi | 17 | $499 |
| Novartis | 34 | $489 |
| GSK | 23 | $408 |
| Organon | 26 | $374 |
| Fresenius Kabi USA, LLC | 13 | $282 |
| Aurinia Pharma U.S., Inc. | 9 | $182 |
| Octapharma USA, Inc. | 3 | $163 |
| Genentech USA, Inc. | 8 | $142 |
| Invivyd Inc | 3 | $77 |
| Sanofi-aventis U.S. LLC | 1 | $70 |
| Mallinckrodt Hospital Products Inc. | 3 | $67 |
| Boehringer Ingelheim | 3 | $65 |
| Kyowa Kirin, Inc. | 2 | $53 |
| Sobi, Inc | 2 | $45 |
| Tersera Therapeutics LLC | 1 | $35 |
| Actelion Pharmaceuticals US, Inc. | 1 | $28 |
| Medtronic | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Cumberland Pharmaceuticals, Inc. | 2 | $25 |
| Antares Pharma, Inc. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Bioventus LLC | 1 | $22 |
| Fidia Pharma USA Inc. | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $18 |
| Radius Health, Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $17 |
| Biocon Biologics Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tremfya$125
- SIMPONI ARIA$125
- Otezla$122
- Cimzia$118
How this compares
$16,651 in reported general payments places this provider in the 95th percentile of 1,490 medical providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 18 | $123,642 |
| Orencia ClickjectAbatacept | 19 | $114,000 |
| SimponiGolimumab | 18 | $106,952 |
| Xeljanz XrTofacitinib Citrate | 15 | $85,290 |
| Actemra ActpenTocilizumab | 22 | $78,628 |
| KevzaraSarilumab | 15 | $65,912 |
| Cimzia (2 Pack)Certolizumab Pegol | 11 | $59,546 |
| Hydroxychloroquine Sulfate | 248 | $10,136 |
| RasuvoMethotrexate/Pf | 11 | $6,062 |
| MethotrexateMethotrexate Sodium | 217 | $5,635 |
| Leflunomide | 76 | $3,670 |
| Celecoxib | 45 | $3,008 |
| Sulfasalazine | 73 | $2,976 |
| Mycophenolate Mofetil | 14 | $1,934 |
| Prednisone | 218 | $1,670 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $2,232 | $123,64218 claims |
| Johnson & JohnsonSimponi | $1,388 | $106,95218 claims |
| SanofiKevzara | $499 | $65,91215 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,878 | $59,54611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,490 medical providers in Texas.
Other medical in Sugar Land
- Jennifer HendersonSugar Land$19K
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Shakira CabreraSan Antonio$116K
- Danny DeckardDallas$101K
- Courtney AldridgeSan Antonio$89K
- Janine ShinnDallas$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.